

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

**Complete if Known**

Application Number	09/814,558
Filing Date	March 22, 2001
First Named Inventor	Lazarus et al.
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	209897

Sheet	1	of	3
-------	---	----	---

[illegible][illegible]

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	A C	ABRASH et al., Biochemistry, 2(5):947-953, Sept.-Oct. (1963)		
	A D	ARAKAWA et al., Transplantation, 53(4): 951-953, April (1992)		
	A E	ARAKAWA et al., Transplantation Pro., 24(2):696-697, April (1992)		
	A F	ARAKAWA et al., Transplantation Pro., 25(1):738-740, February (1993)		
	A G	BALBONI et al., Biol. Chem., 378:19-29, January (1997)		


David L. H.

Date Considered

9/27/01

- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box



Substitute for form 1449A/B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

## **Complete if Known**

Sheet	2	of	3	Application Number	09/814,558
				Filing Date	March 22, 2001
				First Named Inventor	Lazarus et al.
				Group Art Unit	<del>1845</del> 1653
				Examiner Name	
				Attorney Docket Number	209897

## **OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
DL	AH	BORCH et al., J. Org. Chem., 37(10):1673-1674 (1972) ✓		
	AI	BRYANT et al., Biol. Chem, 378:107-114, February (1997) ✓		
	AJ	BRYANT et al., Trends in Pharmacol. Sci., 18: 42-46 (1998) ✓		
	AK	CALLAGHAN et al., J. Biol. Chem., 268(21):16059-16064, July 25 (1993) ✓		
	AL	CAPASSO et al., Int. J. Peptide Protein Res., 45:567-573 (1995) ✓		
	AM	CARPENTER et al., J. Am. Chem. Soc., 116(19):8450-8458 (1994) ✓		
	AN	CHAPPELL, Lancet, 343:556, March 5 (1994) ✓		
	AO	CRABB et al., J. Chem. Soc., Perkins Transactions II, 370-378 (1977) ✓		
	AP	CRESCENZI et al., Eur. J. Biochem., 247:66-73 (1997) ✓		
	AQ	DYGOS et al., Synthesis, 741-743, August (1992) ✓		
DL	AR	ERMISCH et al., Phys. Rev., 73(3):489-527, July (1993) ✓		
	AS	FLIPPEN-ANDERSON et al., J. Peptide Res., 49:384-393 (1997) ✓		
	AT	FORD et al., Cancer Research, 50:1748-1756, March 15 (1990) ✓		
	AU	FROEHLICH et al., Alcohol Clin. Exp. Res., 20(8):181A-186A, November Supp. (1996) ✓		
	AV	GUERRINI et al., Bioorg. Med. Chem., 6:57-62 (1998) ✓		
	AW	HAYASHI et al., Chem. Pharm. Bull., 31(1):312-314 (1983) ✓		
	AX	HOUSE et al., Neurosci. Lett., 198:119-122 (1995) ✓		
	AY	JONES et al., J. of Pharm. Exp. Thera., 262(2):638-645 (1992) ✓		
	AZ	KERTÉSZ et al., J. Labelled Cpd. and Radiopharm., XLI:1083-1091 (1998) ✓		
	BA	LAZARUS et al., J. Biol. Chem., 264(1):354-362, January 5 (1989) ✓		
DL	BB	LAZARUS et al., Biochem. Biophys. Res. Comm., 178(1):110-115, July 15 (1991) ✓		
	BC	LAZARUS et al., Drug Devel. Today, 3(6):284-294, June 6 (1998) ✓		
	BD	LAZARUS et al., Int'l Symp. on Peptide Chem. and Biol., Changchung, PRC (1999) ✓		
	BE	LENSING et al., Neuropsychobiology, 31:16-23 (1995) ✓		
	BF	LINNER et al., Eur. J. of Pharmacol., 354:R3-R5 (1998) ✓		
	BG	MARSDEN et al., Int. J. Peptide Protein Res., 41:313-316 (1993) ✓		
	BH	MATTHES et al., Nature, 383:819-823, October 31 (1996) ✓		
	BI	MENKENS et al., Eur. J of Pharmacol., 219:345-346 (1992) ✓		
	BJ	MOSBERG et al., Letters in Peptide Science, 1:69-72 (1994) ✓		

Examiner Signature	David Lester	Date Considered	9/27/01
-----------------------	--------------	--------------------	---------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).



+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).